EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Development of a Bedside Decision Tree for Postexacerbation Risk Stratification: Translating Neuroimmune Biomarker Dynamics Into Clinical Practice

Cheng Chen, Shanshan Liu iD, Jian Dong iD

Canadian Respiratory Journal · 2026-01 · 2026 (1)

DOI: 10.1155/carj/3591021 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Canadian Respiratory Journal, online erschienen am 29.07.2026. Verfasst von Cheng Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Union Jiangbei Hospital, Huazhong University of Science and Technology, Wuhan Hubei, 430100, Ch…. Hauptthemen laut MEDLINE: Decision Trees, Pulmonary Disease, Chronic Obstructive. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Platform Collaborative Research Fund of the People's Hospital of Caidian District, Wuhan, China, Medical Science Research Project of the Wuhan Municipal Health Commission, Hubei Province, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is characterized by systemic inflammatory response and neuroimmune dysregulation. The dynamic changes of certain key neuroimmune biomarkers during the course of AECOPD and their impact on long‐term patient outcomes have not been thoroughly studied.

Objective

This study aims to develop a bedside clinical decision tree based on neuroimmune biomarker dynamics to stratify post‐AECOPD patient risk and guide personalized discharge planning.

Methods

This prospective observational study included 273 patients hospitalized due to AECOPD. Serum levels of brain‐derived neurotrophic factor (BDNF), programmed cell death protein 1 (PD‐1), matrix metalloproteinase‐9 (MMP‐9), and inflammatory cytokines (IL‐1β, IL‐6, IL‐10, and TNF‐α) were measured within 24 h of admission (T1) and within 48 h after clinical stability at discharge (T2). Unsupervised clustering analysis was performed based on the dynamic changes in biomarkers, and multivariable logistic regression was used to assess their association with 90‐day clinical outcomes (acute exacerbation, readmission). Additionally, a biomarker‐based decision tree model was developed, and its performance was compared with traditional clinical assessment methods.

Results

Three distinct biomarker response patterns were identified: “Coordinated Improvement ” (60.0%), “Inflammatory Rebound” (27.8%), and “Poor Neuro‐repair” (12.1%). Among them, the “Poor Neuro‐repair” phenotype was the strongest independent predictor of acute exacerbation events at 90 days (adjusted OR 3.42, 95% CI 1.78–6.57, p < 0.001). The dynamic change in BDNF (ΔBDNF) showed predictive value for acute exacerbation events (AUC 0.84). The biomarker‐based decision tree model classified patients into four risk levels, with significant differences in the 30‐day event incidence (ranging from 3.6% to 68.4%). Its predictive accuracy (AUC 0.87) was markedly superior to that of clinical judgment (AUC 0.74) and the GOLD standard (AUC 0.68).

Conclusions

The biomarker response patterns after acute exacerbation, particularly the “Poor Neuro‐repair” phenotype and its dynamic changes in BDNF, are closely associated with short‐term clinical outcomes. The decision tree model developed based on this information provides a preliminary approach for risk stratification and discharge planning in AECOPD patients, demonstrating superior efficacy compared to traditional clinical assessment methods.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Decision TreesPulmonary Disease, Chronic ObstructiveHumansBiomarkersFemaleProspective StudiesMaleRisk AssessmentBrain-Derived Neurotrophic FactorAgedDisease ProgressionCytokinesMiddle AgedMatrix Metalloproteinase 9

Stichwörter der Autor:innen

acute exacerbationbiomarkersbrain-derived neurotrophic factorchronic obstructive pulmonary diseasedecision treeprognosisrisk stratification

Substanzen

BiomarkersBrain-Derived Neurotrophic FactorCytokinesMatrix Metalloproteinase 9

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Union Jiangbei Hospital, Huazhong University of Science and Technology, Wuhan Hubei, 430100, China, hust.edu.cn.
  • Department of Neurology, Union Jiangbei Hospital, Huazhong University of Science and Technology, Wuhan Hubei, 430100, China, hust.edu.cn.

ORCID-Profile: Shanshan Liu, Jian Dong

Förderung

  • Platform Collaborative Research Fund of the People's Hospital of Caidian District, Wuhan, China
  • Medical Science Research Project of the Wuhan Municipal Health Commission, Hubei Province, China

Zitieren

APA

Chen, C., Liu, S., & Dong, J. (2026). Development of a Bedside Decision Tree for Postexacerbation Risk Stratification: Translating Neuroimmune Biomarker Dynamics Into Clinical Practice. Canadian Respiratory Journal, 2026(1). https://doi.org/10.1155/carj/3591021

Vancouver

Chen C, Liu S, Dong J. Development of a Bedside Decision Tree for Postexacerbation Risk Stratification: Translating Neuroimmune Biomarker Dynamics Into Clinical Practice. Canadian Respiratory Journal. 2026;2026(1). doi:10.1155/carj/3591021

BibTeX
@article{Chen2026,
  author = {Chen, Cheng and Liu, Shanshan and Dong, Jian},
  title = {Development of a Bedside Decision Tree for Postexacerbation Risk Stratification: Translating Neuroimmune Biomarker Dynamics Into Clinical Practice},
  journal = {Canadian Respiratory Journal},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/carj/3591021}
}
Kostenlos starten →